Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Holly Austin

Physician Assistant Clarksville, TN Physician Assistant

NPI 1437403144 CMS profile 10708149

651 Dunlop Ln, Clarksville, TN 37040

Open in the dashboard

General payments

$1,749

86 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Holly Austin of Clarksville, TN is reported in the CMS Open Payments database as having received $1,749 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $312 16
2024 General $862 46
2023 General $426 23
2022 General $149 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Holly Austin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Holly Austin were reported at $312. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Holly Austin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $149 $155 $48–$522 $149
2023 $426 $167 $52–$557 $160
2024 $862 $178 $55–$600 $164
2025 $312 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $582 31 payments
  2. AstraZeneca Pharmaceuticals LP $312 16 payments
  3. Lilly USA, LLC $206 12 payments
  4. Sanofi-Aventis U.S. LLC $149 1 payment
  5. AbbVie, Inc. $119 5 payments
  6. Amgen Inc. $62 3 payments
  7. Exact Sciences Corporation $44 3 payments
  8. Phathom Pharmaceuticals, Inc. $39 2 payments
  9. Merck Sharp & Dohme Corporation $36 2 payments
  10. Mylan Specialty L.P. $34 2 payments
  11. Other $165 9 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,749 86 payments
Products named General payments · program years 2022–2025
  1. RYBELSUS $437 20 payments
  2. Ozempic $414 19 payments
  3. BREZTRI $152 7 payments
  4. MOUNJARO $150 9 payments
  5. Wegovy $145 11 payments
  6. FARXIGA $141 6 payments
  7. AIRSUPRA $137 5 payments
  8. ZEPBOUND $134 8 payments
  9. UBRELVY $68 3 payments
  10. Otezla $62 3 payments
  11. Other $658 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

4,092

Median for Physician Assistant: 241

Drug cost

$394,761

Median for Physician Assistant: $4,110

Branded share of claims

23.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 66 $107,516
Mounjaro Tirzepatide Brand 61 $64,482
Jardiance Empagliflozin Brand 40 $34,101
Eliquis Apixaban Brand 42 $28,466
Trulicity Dulaglutide Brand 24 $23,289
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 23 $21,581
Januvia Sitagliptin Phosphate Brand 21 $20,211
Wegovy Semaglutide Brand 13 $18,369
Farxiga Dapagliflozin Propanediol Brand 15 $13,825
Xarelto Rivaroxaban Brand 17 $11,902

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$29,750

Of which drugs: $1,552

Medicare patients

206

Average age 71

Services billed

1,151

127 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 32%
Ischemic heart disease 22%
Chronic kidney disease 20%
Depression 19%
COPD 18%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,044
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 16 66 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $117
$117 — —
Ozempic
  • Novo Nordisk Inc $117
$117 66 —
Wegovy
  • Novo Nordisk Inc $105
$105 13 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $65
$65 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record